Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma

Trial Profile

Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma

Suspended
Phase of Trial: Phase II/III

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Busulfan (Primary) ; Melphalan (Primary) ; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Filgrastim; Mesna; Topotecan; Vincristine
  • Indications Neuroblastoma
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 14 Jun 2013 New source identified and integrated (Vanderbilt-Ingram Cancer Center; COGANBL12P1).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top